Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Benefit of neuroprotection in acute ischaemic stroke, shall we dare to hope?

Akhtar A, Kamal AK.

J Pak Med Assoc. 2013 Jun;63(6):792. No abstract available.

2.

Ginsenoside Rd attenuates redox imbalance and improves stroke outcome after focal cerebral ischemia in aged mice.

Ye R, Kong X, Yang Q, Zhang Y, Han J, Zhao G.

Neuropharmacology. 2011 Sep;61(4):815-24. doi: 10.1016/j.neuropharm.2011.05.029. Epub 2011 Jun 2.

PMID:
21664366
3.

Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR. A safety and tolerability study.

Diener HC, AlKhedr A, Busse O, Hacke W, Zingmark PH, Jonsson N, Basun H; Study group.

J Neurol. 2002 May;249(5):561-8.

PMID:
12021946
4.

Sanchi for acute ischaemic stroke.

Chen X, Zhou M, Li Q, Yang J, Zhang Y, Zhang D, Kong S, Zhou D, He L.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006305. doi: 10.1002/14651858.CD006305.pub2. Review.

PMID:
18843711
5.

Rapid neurological recovery after intravenous tissue plasminogen activator in stroke: prognostic factors and outcome.

Machumpurath B, Davis SM, Yan B.

Cerebrovasc Dis. 2011;31(3):278-83. doi: 10.1159/000322564. Epub 2010 Dec 21.

PMID:
21178353
6.

Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.

Diedler J, Ahmed N, Sykora M, Uyttenboogaart M, Overgaard K, Luijckx GJ, Soinne L, Ford GA, Lees KR, Wahlgren N, Ringleb P.

Stroke. 2010 Feb;41(2):288-94. doi: 10.1161/STROKEAHA.109.559724. Epub 2010 Jan 7.

7.

Predicting functional outcome and symptomatic intracranial hemorrhage in patients with acute ischemic stroke: a glimpse into the crystal ball?

Ntaios G, Papavasileiou V, Michel P, Tatlisumak T, Strbian D.

Stroke. 2015 Mar;46(3):899-908. doi: 10.1161/STROKEAHA.114.003665. Epub 2015 Feb 5. Review. No abstract available.

8.

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A.

Lancet. 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. Epub 2012 May 23. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

9.

Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage.

Choi DW.

Trends Neurosci. 1988 Oct;11(10):465-9. Review. No abstract available.

PMID:
2469166
10.

Low admission serum albumin as prognostic determinant of 30-day case fatality and adverse functional outcome following acute ischemic stroke.

Abubakar S, Sabir A, Ndakotsu M, Imam M, Tasiu M.

Pan Afr Med J. 2013;14:53. doi: 10.11604/pamj.2013.14.53.1941. Epub 2013 Feb 7.

11.

Intranasal ginsenoside Rb1 targets the brain and ameliorates cerebral ischemia/reperfusion injury in rats.

Lu T, Jiang Y, Zhou Z, Yue X, Wei N, Chen Z, Ma M, Xu G, Liu X.

Biol Pharm Bull. 2011;34(8):1319-24.

12.

[The use of cereton in ischemic stroke].

Maslova NN, Pysina AM.

Zh Nevrol Psikhiatr Im S S Korsakova. 2008;Suppl 23:21-2. Russian. No abstract available.

PMID:
19431273
13.

Remote ischemic perconditioning in thrombolysed stroke patients: randomized study of activating endogenous neuroprotection - design and MRI measurements.

Hougaard KD, Hjort N, Zeidler D, Sørensen L, Nørgaard A, Thomsen RB, Jonsdottir K, Mouridsen K, Hansen TM, Cho TH, Nielsen TT, Bøtker HE, Østergaard L, Andersen G.

Int J Stroke. 2013 Feb;8(2):141-6. doi: 10.1111/j.1747-4949.2012.00786.x. Epub 2012 Mar 30.

PMID:
22463392
14.

[Neuroprotection in brain ischemia--doubts and hopes].

Zádor Z, Benyó Z, Lacza Z, Hortobágyi T Sr, Harkány T, Hortobágyi T.

Ideggyogy Sz. 2004 Mar 20;57(3-4):81-93. Review. Hungarian.

PMID:
15133909
15.

Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke.

Miedema I, Uyttenboogaart M, Koopman K, De Keyser J, Luijckx GJ.

Cerebrovasc Dis. 2010 Feb;29(3):263-7. doi: 10.1159/000275500. Epub 2010 Jan 15.

PMID:
20090317
16.

Clinical outcome and imaging follow-up in acute stroke patients with normal perfusion CT and normal CT angiography.

Eckert B, Küsel T, Leppien A, Michels P, Müller-Jensen A, Fiehler J.

Neuroradiology. 2011 Feb;53(2):79-88. doi: 10.1007/s00234-010-0702-9. Epub 2010 Apr 27.

PMID:
20422406
17.

Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic stroke.

Ducrocq X, Bracard S, Taillandier L, Anxionnat R, Lacour JC, Guillemin F, Debouverie M, Bollaert PE.

J Neuroradiol. 2005 Jan;32(1):26-32.

18.

Ischaemic stroke in young people: a prospective and long-term follow-up study.

Musolino R, La Spina P, Granata A, Gallitto G, Leggiadro N, Carerj S, Manganaro A, Tripodi F, Epifanio A, Gangemi S, Di Perri R.

Cerebrovasc Dis. 2003;15(1-2):121-8.

PMID:
12499721
19.

Implant for augmentation of cerebral blood flow trial 1: a pilot study evaluating the safety and effectiveness of the Ischaemic Stroke System for treatment of acute ischaemic stroke.

Khurana D, Kaul S, Bornstein NM; ImpACT-1 Study Group.

Int J Stroke. 2009 Dec;4(6):480-5. doi: 10.1111/j.1747-4949.2009.00385.x.

PMID:
19930060
20.

Neuroprotection in acute ischaemic stroke. Current status and future potential.

Lutsep HL, Clark WM.

Drugs R D. 1999 Jan;1(1):3-8. Review.

PMID:
10565968
Items per page

Supplemental Content

Write to the Help Desk